# Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet

> **NCT02993224** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 148 (actual)

## Conditions studied

- Transfusion-dependent Thalassemia
- Non-transfusion-dependent Thalassemia

## Interventions

- **DRUG:** Deferasirox dispersable tablet (DT)
- **DRUG:** Deferasirox film coated tablet (FCT)

## Key facts

- **NCT ID:** NCT02993224
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-27
- **Primary completion:** 2020-01-29
- **Final completion:** 2021-03-11
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2021-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02993224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02993224, "Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02993224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*